Royalmount Pharma and US National Cancer Institute Commence Patient Enrolment in a Phase I Clinical Trial With RM1812
Posted on: Thursday, 25 January 2007, 12:00 CST
Royalmount Pharma, an emerging pharmaceutical company, is pleased to announce that the U.S. National Cancer Institute ("NCI") has commenced enrolment in a Phase I repeat-dose clinical study with RM1812.
The safety and pharmacokinetics of RM1812 following repeat daily dosing will be investigated in healthy volunteers. Subjects will receive study drug by oral administration once daily for twenty-nine days. Four dose levels are planned with ten participants per dose level.
Royalmount Pharma is collaborating with the NCI under a Clinical Trial Agreement for the evaluation of RM1812 as a cancer chemopreventive agent. "This trial is significant step forward in the development of RM1812 as a potential cancer chemopreventive agent and as such is an important milestone for Royalmount Pharma,"said Dr. Tristan Booth, Chief Scientific Officer of Royalmount Pharma. "Safety is of paramount concern in this indication and RM1812 has already demonstrated a good safety profile in preclinical and single-dose clinical testing conducted to date."
Participating clinical sites are the University of Michigan Medical Center, Ann Arbor, MI, US and the University of Leicester, Leicester Royal Infirmary, Leicester, UK.
About RM1812
The clinical utility of RM1812 is being investigated in several patented indications. The compound has been successfully evaluated in oral single-dose Phase I clinical trials in a total of ninety subjects, demonstrating a good safety profile of the drug in humans. The current repeat-dose trial is a standard clinical requirement before planned future studies in patients. In addition, RM1812 has completed a multi-center Phase IIa clinical trial of a topical formulation for the treatment of recurrent herpes simplex labialis (HSV-1 or cold sores) and the company is now seeking a development and commercialization partner.
About the National Cancer Institute
The National Cancer Institute, an agency of the National Institutes of Health (NIH), is the U.S. Federal Government's principal agency for cancer research and training.
About Royalmount Pharma
Royalmount Pharma is an emerging pharmaceutical company focused on developing and commercializing innovative and affordable medicines to address underserved clinical demand in markets including inflammatory diseases and cancer.
Contacts: Royalmount Pharma Inc. Toni Rinow Ph.D. Vice President, Corporate Development 514-340-7849 514-344-3454 (FAX) trinow@royalmountpharma.comwww.royalmountpharma.com.
SOURCE: Royalmount Pharma Inc.
Source: MARKET WIRE
Related Articles
- Enobia Pharma Initiates Dosing in Hypophosphatasia Study
- FDA Lifts Clinical Hold on Vion's Phase III Trial of Leukemia Drug
- Chimerix Starts Multi-Dose Trial for Smallpox Infection
- EpiCept Reports on Cancer Compound Trial Developments
- Murphy Foundation Launches First-Ever Cancer Prevention Trial in Pet Dogs
- Pancreatic Cancer Therapy Trial Starts
- Alcoa's Lafayette Operations Receives Occupational Excellence Achievement Award for Safety Excellence From National Safety Council
- Study looks at factors influencing African-American women's decisions to join cancer screening trial
- ABF Receives National Safety Council Award
- pSivida Limited Reports Positive Phase IIa Trial Results in Liver Cancer; BrachySil Trial Confirms Safety and Tumor Regression in Further Patients
 |
 |
User Comments (0)
RSS Feeds